[go: up one dir, main page]

DK1089726T3 - Præparat omfattende beta-hydroxy-beta-methylsmørsyre og mindst en aminosyre - Google Patents

Præparat omfattende beta-hydroxy-beta-methylsmørsyre og mindst en aminosyre

Info

Publication number
DK1089726T3
DK1089726T3 DK99930567T DK99930567T DK1089726T3 DK 1089726 T3 DK1089726 T3 DK 1089726T3 DK 99930567 T DK99930567 T DK 99930567T DK 99930567 T DK99930567 T DK 99930567T DK 1089726 T3 DK1089726 T3 DK 1089726T3
Authority
DK
Denmark
Prior art keywords
beta
hydroxy
composition
acid
amino acid
Prior art date
Application number
DK99930567T
Other languages
English (en)
Inventor
Steven L Nissen
Naji M Abumrad
Original Assignee
Univ Iowa State Res Found Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22292520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1089726(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Iowa State Res Found Inc filed Critical Univ Iowa State Res Found Inc
Application granted granted Critical
Publication of DK1089726T3 publication Critical patent/DK1089726T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
DK99930567T 1998-06-23 1999-06-23 Præparat omfattende beta-hydroxy-beta-methylsmørsyre og mindst en aminosyre DK1089726T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/102,941 US6031000A (en) 1998-06-23 1998-06-23 Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
PCT/US1999/014097 WO1999066917A2 (en) 1998-06-23 1999-06-23 Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid

Publications (1)

Publication Number Publication Date
DK1089726T3 true DK1089726T3 (da) 2002-07-22

Family

ID=22292520

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99930567T DK1089726T3 (da) 1998-06-23 1999-06-23 Præparat omfattende beta-hydroxy-beta-methylsmørsyre og mindst en aminosyre

Country Status (12)

Country Link
US (1) US6031000A (da)
EP (1) EP1089726B1 (da)
JP (2) JP5064609B2 (da)
AU (1) AU756353B2 (da)
CA (1) CA2334761C (da)
DE (1) DE69901396T2 (da)
DK (1) DK1089726T3 (da)
ES (1) ES2177293T3 (da)
NO (2) NO329914B1 (da)
NZ (1) NZ508395A (da)
PL (1) PL195623B1 (da)
WO (1) WO1999066917A2 (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3362350B2 (ja) * 1997-10-16 2003-01-07 味の素株式会社 反芻動物の肥育方法
US20040220266A1 (en) * 2002-09-09 2004-11-04 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040106678A1 (en) * 2002-09-17 2004-06-03 Dobbins Thomas A Compositions for the parenteral administration of calcium and magnesium
US6812249B2 (en) * 2003-03-04 2004-11-02 Sal Abraham Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
EP1973426A2 (en) * 2005-11-03 2008-10-01 Southwest Immunology Inc. Compositions for preventing and reducing delayed onset muscle soreness
CN101316582A (zh) * 2005-11-30 2008-12-03 雀巢技术公司 治疗肌肉损失的方法
CA2632262C (en) * 2005-12-19 2015-04-07 Abbott Laboratories Method of using .beta.-hydroxy-.beta.-methylbutyrate
US8324175B2 (en) * 2006-02-16 2012-12-04 Young Hee Ko Compositions and methods for the treatment of cancer
US7754693B2 (en) * 2006-02-16 2010-07-13 Young Hee Ko Composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer
EP2381784B1 (en) 2008-12-09 2018-07-11 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9259430B2 (en) 2008-12-09 2016-02-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9770424B2 (en) * 2008-12-09 2017-09-26 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9539224B2 (en) 2008-12-09 2017-01-10 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US11173167B2 (en) 2008-12-09 2021-11-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9707241B2 (en) 2008-12-09 2017-07-18 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
WO2010088564A2 (en) * 2009-01-29 2010-08-05 Young Hee Ko Compositions and methods for the treatment of cancer
EP2289555A1 (en) * 2009-08-24 2011-03-02 OrgaNext Research B.V. Method of treating frailty
ES2608483T3 (es) * 2009-12-18 2017-04-11 Metabolic Technologies, Inc. Método mejorado de administración de beta-hidroxi-beta-metilbutirato (HMB)
PE20121730A1 (es) 2010-01-29 2013-01-13 Abbott Lab Liquidos nutricionales envasados asepticamente que comprenden beta-hidroxi-beta-metilbutirato (hmb)
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
ES2481865T3 (es) 2010-01-29 2014-07-31 Abbott Laboratories Emulsiones nutricionales que comprenden HMB de calcio
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
RU2017129378A (ru) 2011-07-15 2019-02-04 Нусерт Сайенсиз, Инк. Композиции и способы модулирования метаболических путей
US9327001B2 (en) 2011-11-03 2016-05-03 University Of Florida Research Foundation, Inc. Nutritional supplement for weight management
EP3437649A1 (en) * 2011-11-21 2019-02-06 Emmaus Medical Inc. Methods and compositions for the treatment of diabetes and related symptoms
ES2668885T3 (es) 2012-01-11 2018-05-22 Abbott Laboratories Combinación de beta-hidroxi beta-metilbutírico, arginina, y glutamina para su uso en el tratamiento de úlceras diabéticas
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
HUE065064T2 (hu) 2012-09-10 2024-05-28 Metabolic Tech Llc HMB-t éa ATP-t tartalmazó készítmények és felhasználásuk
IN2015DN03322A (da) 2012-09-21 2015-10-09 Abbott Lab
WO2014047493A1 (en) * 2012-09-21 2014-03-27 Abbott Laboratories Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate and protein
AU2013344753B2 (en) 2012-11-13 2018-09-27 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
CN105188695A (zh) * 2013-03-14 2015-12-23 雅培制药有限公司 与长期体力活动不足有关的胰岛素抗性的治疗
CA2902879C (en) 2013-03-15 2023-09-26 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
US20150057350A1 (en) * 2013-08-23 2015-02-26 Abbott Laboratories Fibrosis biomarkers and methods of using same
CN106456997B (zh) 2014-02-27 2018-12-28 纽斯尔特科学公司 用于减少或预防肝性脂肪变性的组合物和方法
US20160346238A1 (en) * 2015-06-01 2016-12-01 Metabolic Technologies, Inc. Compositions and Methods of Use of -hydroxy--methylbutyrate (HMB) for Decreasing Fat Mass
US12208073B2 (en) 2015-09-16 2025-01-28 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
WO2017049093A1 (en) 2015-09-16 2017-03-23 Metabolic Technologies, Inc. COMPOSITIONS AND METHODS OF USE OF β-HYDROXY-β-METHYLBUTYRATE (HMB) FOR ENHANCING RECOVERY FROM SOFT TISSUE TRAUMA
JP6875288B2 (ja) * 2015-11-19 2021-05-19 協和発酵バイオ株式会社 ３−ヒドロキシイソ吉草酸の一価カチオン塩の結晶および該結晶の製造方法
CN109641135A (zh) 2016-01-21 2019-04-16 代谢科技有限公司 β-羟基-β-甲基丁酸(HMB)用于调节自噬和噬脂的组合物和方法
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
MY209347A (en) * 2016-04-19 2025-07-03 Axcess Global Sciences Llc Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
AU2017282515A1 (en) 2016-06-24 2019-01-17 Otsuka Pharmaceutical Factory, Inc. Crystal of β-hydroxy β-methylbutyric acid amino acid salt and production method therefor
EP3528801B1 (en) 2016-10-21 2024-07-17 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) and probiotics
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US12171735B2 (en) 2017-04-19 2024-12-24 Axcess Global Sciences, Llc Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
CN111295187A (zh) 2017-08-14 2020-06-16 胺细拉健康公司 用于治疗肝脏疾病的氨基酸组合物
MX2020007008A (es) * 2018-01-05 2021-04-28 Texas Tech Univ Office Of Research Commercialization COMPOSICIONES Y MÉTODOS DE USO DE ß- HIDROXI-ß-METILBUTIRATO (HMB) ASOCIADO CON AYUNO INTERMITENTE.
MA52971A (fr) 2018-06-20 2021-04-28 Axcella Health Inc Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157022A (en) * 1989-11-22 1992-10-20 Adrian Barbul Method for reducing blood cholesterol using arginine
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US4992470A (en) * 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
DE69327468T2 (de) * 1992-09-16 2000-05-11 Iowa State University Research Foundation, Inc. Verfahren zur reduktion der blutspiegel von gesamtcholesterin und ldl-cholesterin
US5348979A (en) * 1992-12-23 1994-09-20 Iowa State University Research Foundation Inc. Method of promoting nitrogen retention in humans
AU6102994A (en) * 1993-02-11 1994-08-29 Iowa State University Research Foundation Inc. Method of enhancing nutritional value of colostrum and first milk of pregnant mammals
US5726146A (en) * 1994-12-06 1998-03-10 Natural Supplement Association, Incorporated Non-steroidal, anabolic dietary supplement and method to increase lean mass without linked increase fat mass
US5756469A (en) * 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
DE29707308U1 (de) * 1997-04-23 1997-06-26 Kunz, Armin, 66450 Bexbach Präparat zur Muskelerhaltung bzw. zur Förderung des Muskelaufbaus

Also Published As

Publication number Publication date
PL195623B1 (pl) 2007-10-31
NO332374B1 (no) 2012-09-10
WO1999066917A3 (en) 2000-04-20
PL344589A1 (en) 2001-11-05
JP5690261B2 (ja) 2015-03-25
NO20101440L (no) 2001-02-20
WO1999066917A2 (en) 1999-12-29
DE69901396D1 (de) 2002-06-06
NO20006633L (no) 2001-02-20
ES2177293T3 (es) 2002-12-01
CA2334761C (en) 2009-04-28
EP1089726A2 (en) 2001-04-11
NZ508395A (en) 2003-09-26
NO20006633D0 (no) 2000-12-22
JP2012102118A (ja) 2012-05-31
EP1089726B1 (en) 2002-05-02
JP5064609B2 (ja) 2012-10-31
AU4708099A (en) 2000-01-10
CA2334761A1 (en) 1999-12-29
AU756353B2 (en) 2003-01-09
US6031000A (en) 2000-02-29
DE69901396T2 (de) 2002-08-29
NO329914B1 (no) 2011-01-24
JP2002518440A (ja) 2002-06-25

Similar Documents

Publication Publication Date Title
DK1089726T3 (da) Præparat omfattende beta-hydroxy-beta-methylsmørsyre og mindst en aminosyre
NO20032753D0 (no) Forbindelse og anvendelse derav
DK1454907T3 (da) Quninazolin og pyridopyrmidin-derivativer
NO20022086D0 (no) Antidiabetisk formulering og fremgangsmåte
DE69905371D1 (de) Härtbare zusammensetzung
DE69824961D1 (de) Härtbare zusammensetzung
NO20006488D0 (no) Sammensetning og anvendelse
NO20022334L (no) Ny sammensetning og anvendelse
DK0723772T3 (da) Reducerende sammensætning omfattende en basisk aminosyre og en kationisk polymer
DE69928270D1 (de) Neutraler aminosäurentransporter und korrespondierendes gen
DE69931076D1 (de) Härtbare mischungen
NO20010078L (no) Fenoksyeddiksyrederivat og farmasøytisk sammensetning omfattende det samme
DK1112003T3 (da) Ny sammensætning og anvendelse
DK1100769T3 (da) Aminomethylcarboxylsyrederivater
PT1139761E (pt) Composicoes herbicidas e concentrados tensioactivos
ZA994406B (en) Meta-azacyclic amino benzoic acid and derivatives thereof.
DE69811277D1 (de) Aminierungsverfahren
NO20000425D0 (no) Collagen type I og type III klebende sammensetninger
DE69720335D1 (de) Recombinante Fructosyl-Aminosäure-Oxidase
DE59804343D1 (de) Schraubwerkzeug
PT878467E (pt) Acidos 6-aminotetra-hidroisoquinolinacarboxilicos e 7-aminotetra-hidroisoquinolinacarboxilicos substituidos
DE69821948D1 (de) Härtbare zusammensetzung
DK1124797T3 (da) N-Arylsulfonyl-aminosyre-omega-amider
NO20001958L (no) Synergistiske sammensetninger omfattende et oksatiazin og et benzotiofen-2-karboksamid-S,S-dioksid
DK1140952T3 (da) Phosphororganiske forbindelser og anvendelse heraf